Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.46 |
| ▸ | KMO | O15229 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24158837 | 0.84 | KDM4E (0.48) | HSD17B10L3MBTL1TDP1POLBALDH1A1 | |
| SCHEMBL960168 | 0.81 | HSD17B10 (0.56) | HSD17B10L3MBTL1TDP1POLBKMO | |
| SCHEMBL21576891 | 0.80 | HSD17B10 (0.44) | HSD17B10L3MBTL1TDP1POLBALDH1A1 | |
| SCHEMBL22572428 | 0.80 | HSD17B10 (0.44) | HSD17B10L3MBTL1TDP1POLBALDH1A1 | |
| SCHEMBL10175541 | 0.78 | LMNA (0.54) | L3MBTL1POLBEGLN3KMOALDH1A1 | |
| SCHEMBL23120471 | 0.78 | L3MBTL1 (0.46) | L3MBTL1TDP1EGLN3KMOALDH1A1 | |
| SCHEMBL16876002 | 0.77 | HSD17B10 (0.49) | HSD17B10L3MBTL1TDP1POLBALDH1A1 | |
| Hydrochloric Acid SCHEMBL28842191 | 0.76 | LMNA (0.52) | L3MBTL1POLBEGLN3KMOALDH1A1 | |
| SCHEMBL23541176 | 0.75 | EGLN3 (0.43) | L3MBTL1TDP1POLBEGLN3KMO | |
| SCHEMBL13805669 | 0.75 | L3MBTL1 (0.47) | L3MBTL1EGLN3KMOALDH1A1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4029868-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12404265-B2 | Substituted pyridine derivatives as SARM1 inhibitors | NURA BIO, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-11970481-B1 | Substituted pyridine derivatives as SARM1 inhibitors | NURA BIO, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| US-20240116901-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | NURA BIO, INC. | 2024-04-11 | — | — | US | disclosed |
| CN-117304130-A | MCL-1 inhibitors | 吉利德科学公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20230339913-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | NURA BIO, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339913-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | NURA BIO, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230312490-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| EP-4192828-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | Nura Bio, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| CN-112118845-B | MCL-1 inhibitors | 吉利德科学公司 | 2023-06-13 | — | — | CN | disclosed |
| US-20190352271-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2019-11-21 | — | — | US | disclosed |
| US-9085572-B2 | 4-(pyridin-3-yl)-2(pyridin-2yl)-1,2-dihydro-3H-pyrazol-3-one derivatives as specific HIF-pyrolyl-4-hydroxylase inhibitors for treating cardiovascular and haematological diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-21 | — | — | US | disclosed |
| US-20120322772-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
| US-8252817-B2 | Dipyridyl-dihydropyrazolones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-08-28 | — | — | US | disclosed |
| CN-101213189-B | 4-(pyridin-3-yl)-2-(pyridin-2-yl)-1,2-dihydro-3h-pyrazol-3-one derivatives as specific hif-prolyl-4-hydroxylase inhibitors for treating cardiovascular and haematological diseases | BAYER HEALTHCARE AG | 2011-06-22 | — | — | CN | disclosed |
| US-20100035906-A1 | Dipyridyl-dihydropyrazolones and their use | BAYER HEALTHCARE AG (DE) | 2010-02-11 | — | — | US | disclosed |
| EP-1877396-B1 | 4-(PYRIDIN-3-YL)-2-(PYRIDIN-2-YL)-1,2-DIHYDRO-3H-PYRAZOL-3-ONE DERIVATIVES AS SPECIFIC HIF-PROLYL-4-HYDROXYLASE INHIBITORS FOR TREATING CARDIOVASCULAR AND HAEMATOLOGICAL DISEASES | BAYER HEALTHCARE AG (DE) | 2009-02-18 | — | — | EP | disclosed |
| CN-101213189-A | 4-(pyridin-3-yl)-2-(pyridin-2-yl)-1,2-dihydro-3h-pyrazol-3-one derivatives as specific hif-prolyl-4-hydroxylase inhibitors for treating cardiovascular and haematological diseases | BAYER HEALTHCARE AG (DE) | 2008-07-02 | — | — | CN | disclosed |
| EP-1877396-A1 | 4-(PYRIDIN-3-YL)-2-(PYRIDIN-2-YL)-1,2-DIHYDRO-3H-PYRAZOL-3-ONE DERIVATIVES AS SPECIFIC HIF-PROLYL-4-HYDROXYLASE INHIBITORS FOR TREATING CARDIOVASCULAR AND HAEMATOLOGICAL DISEASES | Bayer HealthCare AG (DE) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006114213-A1 | 4-(PYRIDIN-3-YL)-2-(PYRIDIN-2-YL)-1,2-DIHYDRO-3H-PYRAZOL-3-ONE DERIVATIVES AS SPECIFIC HIF-PROLYL-4-HYDROXYLASE INHIBITORS FOR TREATING CARDIOVASCULAR AND HAEMATOLOGICAL DISEASES | BAYER HEALTHCARE AG (DE) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404265-B2 | Substituted pyridine derivatives as SARM1 inhibitors | SARM1, SARNP, ADRM1 | HSD17B10 4060/4885L3MBTL1 949/4885TDP1 232/4885 |
| US-20190352271-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | HSD17B10 3674/4885L3MBTL1 616/4885TDP1 764/4885 |
| US-20230312490-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | HSD17B10 3674/4885L3MBTL1 616/4885TDP1 764/4885 |
| US-11970481-B1 | Substituted pyridine derivatives as SARM1 inhibitors | SARM1, SARNP, ADRM1 | HSD17B10 4060/4885L3MBTL1 949/4885TDP1 232/4885 |
| US-20120322772-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | PPIP5K2, THPO, DPYD | HSD17B10 4405/4885L3MBTL1 3186/4885TDP1 378/4885 |
| US-20230339913-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | SARM1, SARNP, ADRM1 | HSD17B10 4060/4885L3MBTL1 949/4885TDP1 232/4885 |
| US-20100035906-A1 | Dipyridyl-dihydropyrazolones and their use | DPP7, DPP4, QDPR | HSD17B10 3138/4885L3MBTL1 3395/4885TDP1 555/4885 |
| US-20240116901-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | SARM1, SARNP, ADRM1 | HSD17B10 4060/4885L3MBTL1 949/4885TDP1 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.